Bridging Community: Collaborative Efforts in Early Detection and Intervention for Alzheimer’s Disease
Released On
January 22, 2025
Expires On
January 14, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Neurology, Obstetrics & Gynecology, Primary Care, Psychiatry
Topic(s)
Alzheimer's
This activity is provided by MLI
This activity is supported by an educational grant from Lilly.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Physician Associates — maximum of 1.0 AAPA Category 1 CME credit
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for primary care practitioners (including ob/gyns and NPs/PAs), general neurologists, psychiatrists, and other members of the multidisciplinary, interprofessional healthcare team in the U.S. who are uniquely positioned to manage patients at risk of cognitive impairment and Alzheimer’s Disease (AD).
Program Overview
Bridging Community: Collaborative Efforts in Early Detection and Intervention for Alzheimer’s Disease is an innovative educational program tailored for family medicine physicians, as well as primary care practitioners—including OB/GYNs, NPs, PAs—alongside general neurologists, psychiatrists, and other members of the interprofessional healthcare team. This program empowers clinicians who play a pivotal role in identifying and managing patients at risk of early Alzheimer’s disease (AD) and cognitive impairment.
Participants will gain actionable insights from expert faculty, who will explore:
- Evidence-based strategies to enhance brain health by addressing modifiable risk factors for cognitive decline and AD.
- Cutting-edge approaches to the early detection of AD, including the latest in assessments, diagnostics, and treatments.
- Effective communication techniques to engage patients and caregivers in meaningful conversations about brain health and cognitive concerns.
Through case-based discussions and sharing multidisciplinary perspectives, learners will deepen their understanding of clinical challenges and refine their approach to AD patient care. Join us in bridging the gap between early Alzheimer's disease detection and intervention for a brighter future in brain health.
*First FDA approved (May 2025, after recording of this activity) in vitro diagnostic device to test blood (pTau217/ß-Amyloid 1-42 plasma ratio) to aid in diagnosing early symptomatic AD in patients ≥ 55 years.
Learning Objectives
Upon completion of this CE activity, participants should be better able to:
- Integrate strategies into care plans that optimize brain health for patients with factors that increase the risk of cognitive decline and AD
- Describe the latest evidence supporting the need for the early detection of mild cognitive impairment in the AD continuum
- Develop patient-centered communication strategies to address brain health and cognitive concerns with patients and their caregivers
Agenda
- Introduction and pre-assessment
- Integrating Evidence-Based Strategies for Improving Brain Health: Managing Modifiable Risk Factors in Cognitive Decline and AD
- Advanced epidemiology and pathophysiology of cognitive decline and AD
- Recognizing the Critical Role of Early Detection in the AD Continuum to Improve Outcomes: Leveraging Assessment, Advanced Diagnostics, and Treatment Strategies
- Transformative impact of early detection in AD: Detailed exploration of AD as a continuum and the importance of preclinical detection
- Benefits of Early Recognition of Cognitive Impairment
- Taking Advantage of the Medicare Annual Wellness Visit
- The Diagnostic Process
- The Role of Biomarkers in Identifying Patients Early in the Disease Course and Informing Treatment
- Medical Management of Early AD
- Designing Patient-Centered Communication Plans for Discussing Brain Health and Cognitive Concerns
- Effective communication strategies
- Empathetic and clear communication techniques
- Addressing emotional and practical concerns
- Conclusion, Post-Assessment/Post-Test, & Evaluation
Faculty
Ariel Cole, MD, CMD, FAAFP
Director, AdventHealth Geriatric Medicine Fellowship
Geriatrics Clerkship Director, Orlando Campus
Florida State University College of Medicine
Winter Park, FL, USA
Alireza Atri, MD, PhD
Chief Medical Officer, Banner Research
Director, Banner Sun Health Research Institute
Sun City, AZ, USA
Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
University of Rochester School of Medicine
Rochester, NY, USA
Elizabeth Poynor, MD, PhD
Chair, Women's Health and Gynecology Atria Institute
Clinical Professor Obstetrics and Gynecology, NYU Langone
New York, NY, USA
Accreditation Statement
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
AAFP CME Credit
The AAFP has reviewed Bridging Community: Collaborative Efforts in Early Detection and Intervention for Alzheimer's Disease and deemed it acceptable for up to 1.0 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 01/22/2025 to 01/14/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 14, 2026. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioner
The American Academy of Nurse Practitioners (AANP) Certification Board recognizes and accepts continuing education (CE) credits/contact hours from activities approved by AMA,ACCME, ANCC, AANP, and AAFP.
Disclosures of Conflicts of Interest
Disclosure & Conflict of Interest Policy
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Ariel Cole, MD, CMD, FAAFP, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Alireza Atri, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Eisai, Life Molecular Imaging, Novo Nordisk
Research Support/Grant: ACTC, ADCS, Alzheon, Athira, AZ Alzheimer’s Research Consortium and AZ DHS, ATRI, GAP, Biogen, Biohaven, Eisai, Foundation for NIH (FNIH), Gates Ventures, Indiana University, Johns Hopkins, Lilly, NIA/NIH, USC, Vivoryon, Washington University St. Louis
Other: Royalties or licenses: Oxford University Press / Support for attending meetings and/or travel: Alzheimer’s Association (US), Alzheimer’s Disease International (ADI), American Academy of Neurology (AAN), Michael J Fox Foundation (MJFF)
The following relationships have ended within the last 24 months:
Consultant/Advisor: AriBio (ad hoc), Axsome, Lundbeck, Merck, ONO (ad hoc), Prothena, Vaxxinity
Planner/Presenter
Anton P. Porsteinsson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Acadia Pharmaceuticals, Athira, Axsome, Biogen, Bristol Myers Squibb, Cognitive Research Corp, Eisai, IQVIA, Lundbeck, Novartis, ONO Pharmaceuticals, Otsuka, WCG, WebMD, and Xenon
Research Support (grants to institution): Alector, Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech/Roche, Vaccinex, NIA, NIMH, and DOD
Planner/Presenter
Elizabeth Poynor, MD, PhD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Instructions for Participation and Credit
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at [email protected].
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Course Viewing Requirements
Supported Browsers (Desktop/Mobile)
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
About This Activity
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2025 Medical Learning Institute Inc. All Rights Reserved